Use of positron emission tomography in anticancer drug development

被引：21

作者：

Aboagye, EO ^{[1
]}

Price, PM ^{[1
]}

机构：

[1] Hammersmith Hosp, Dept Canc Med, Fac Med, Imperial Coll Sci Technol & Med,PET Oncol Grp, London, England

来源：

INVESTIGATIONAL NEW DRUGS | 2003年 / 21卷 / 02期

关键词：

positron emission tomography; pharmacokinetics; pharmacodynamics; modeling; anticancer; drug development;

D O I：

10.1023/A:1023521412787

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[C-11]thymidine, [F-18]fluorodeoxyglucose, (H2O)-O-15, (CO)-O-15, and receptor ligands.

引用

页码：169 / 181

页数：13

共 54 条

[1]

Aboagye EO, 2001, CANCER RES, V61, P4937

[2]

Aloj L, 1999, CANCER RES, V59, P4709

[3]

ANDERSON H, 2000, P AN M AM SOC CLIN, V19, pA179

[4] Head and neck cancer: Detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET [J].

Anzai, Y ;

Minoshima, S ;

Wolf, GT ;

Wahl, RL .

RADIOLOGY, 1999, 212 (01) :285-290

[5]

Blasberg RG, 2000, CANCER RES, V60, P624

[6]

Brock CS, 2000, BRIT J CANCER, V82, P608

[7] Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? [J].

Brock, CS ;

Meikle, SR ;

Price, P .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (06) :691-705

[8]

CARSON RE, 1984, J NUCL MED, V25, pP88

[9]

Chung JK, 1999, J NUCL MED, V40, P339

[10]

Cunningham Vincent J., 1995, Medicinal Chemistry Research, V5, P79

← 1 2 3 4 5 6 →